Released May 13, 2025, after the close
10-Q filed May 13, 2025, 43 days after period end · 0000950170-25-070380
Q1 2025 · 10-Q
Revenue$12.00K$12.00K −91.4% vs Q1 2024−76.9% vs Q4 2024
Net Income-$13.87M-$13.87M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.25-$0.25 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$14,731,000N/M
Operating Cash Flow-$4,002,000N/M
Margins · derived
Operating margin-122758.3%−112771.2 pt vs Q1 2024
Net margin-115550.0%−106500.7 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $12.00K | $140.00K | $223.00K | $247.00K |
| Net Income | -$13.87M | -$12.67M | -$13.30M | -$32.80M |
| EPS Diluted | -$0.25 | -$0.24 | -$0.25 | -$1.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR